Protocol #: 18-144
Status
Recruiting
Description
This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved in this study are: - Dabrafenib - Trametinib - PDR001
Condition
Metastatic Colorectal Cancer
Interventions
Dabrafenib
Trametinib
PDR001
Phase
Phase 2
Study Type
Interventional
Further Study Details
Primary Outcome:
Overall Response Rate
Number of participants with grade 3, 4 and 5 adverse events
Secondary Outcome:
Progression Free Survival
Disease Control Rate
Duration of Response
Overall Survival
Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001
Estimated Enrollment
25
Study Start Date
October 15, 2018
Eligibility
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer
Clinicaltrials.gov Identifier
NCT03668431

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top